Research output per year
Research output per year
Personal profile
Research interests
The research efforts of my group concentrate on the application of PET imaging in oncology as part of (immunotherapy) drug development and as a tool for patient selection as well as treatment evaluation.
Specialisation
In the clinic I am specialized in the treatment of patients with breast cancer, endocrine tumors and patients who want to participate in phase I clinical trials. My ultimate goal as a medical oncologist is to have an effective cancer treatment for every individual patient.
Education/Academic qualification
PhD
Keywords
- RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Fingerprint
Dive into the research topics where Willemien Menke-van der Houven van Oordt is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S. & Menke-van der Houven van Oordt, C. W., 1 Apr 2020, In: European journal of nuclear medicine and molecular imaging. 47, 4, p. 849-859 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access27 Citations (Scopus) -
Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors
Willemien Menke-van der Houven van Oordt, C., McGeoch, A., Bergstrom, M., McSherry, I., Smith, D. A., Cleveland, M., Al-Azzam, W., Chen, L., Verheul, H., Hoekstra, O. S., Vugts, D. J., Freedman, I., Huisman, M., Matheny, C., van Dongen, G. & Zhang, S., 1 Jan 2019, In: Journal of nuclear medicine. 60, 7, p. 902-909 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access62 Citations (Scopus) -
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Jauw, Y. W. S., Huisman, M. C., Nayak, T. K., Vugts, D. J., Christen, R., Naegelen, V. M., Ruettinger, D., Heil, F., Lammertsma, A. A., Verheul, H. M. W., Hoekstra, O. S., van Dongen, G. A. M. S. & van Oordt, C. W.M.-V. D. H., 22 Jan 2018, In: EJNMMI research. 8, 6.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
Mammatas, L. H., Venema, C. M., Schröder, C. P., de Vet, H. C. W., van Kruchten, M., Glaudemans, A. W. J. M., Yaqub, M. M., Verheul, H. M. W., Boven, E., van der Vegt, B., de Vries, E. F. J., de Vries, E. G. E., Hoekstra, O. S., Hospers, G. A. P. & der Houven van Oordt, C. W. M. V., 19 Apr 2020, In: EJNMMI research. 10, 1, 40.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy
Mammatas, L. H., Yaqub, M., Hendrikse, N. H., Hoekstra, O. S., Honeywell, R. J., Schuit, R. C., Meijerink, M., Schwarte, L. A., Peters, G. J., Verheul, H. M. W., Lammertsma, A. A. & Menke-van der Houven van Oordt, C. W., 1 Jul 2021, In: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62, 7, p. 934-940 7 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile